Prenatal glucocorticoid exposure causes brain damage in adult offspring; however, the underlying mechanisms remain unclear. Melatonin has been shown to have beneficial effects in compromised pregnancies. Pregnant Sprague-Dawley rats were administered vehicle (VEH) or dexamethasone between gestation days 14 and 21. The programming effects of prenatal dexamethasone exposure on the brain were assessed at postnatal days (PND) 7, 42, and ∼120. Melatonin was administered from PND21 to the rats exposed to dexamethasone, and the outcome was assessed at ∼PND120. In total, there were four groups: VEH, vehicle plus melatonin (VEHM), prenatal dexamethasone-exposure (DEX), and prenatal dexamethasone exposure plus melatonin (DEXM). Spatial memory, gross hippocampal morphology, and hippocampal biochemistry were examined. Spatial memory assessed by the Morris water maze showed no significant differences among the four groups. Brain magnetic resonance imaging showed that all rats with prenatal dexamethasone exposure (DEX + DEXM) exhibited increased T2-weighted signals in the hippocampus. There were no significant differences in the levels of mRNA expression of hippocampal reln, which encodes reelin, and GAD1, which encodes glutamic acid decarboxylase 67, at PND7. At both PND42 and ∼PND120, reln and GAD1 mRNA expression levels were decreased. At ∼PND120, melatonin restored the reduced levels of hippocampal reln and GAD1 mRNA expression in the DEXM group. In addition, melatonin restored the reln mRNA expression levels by (1) reducing DNA methyltransferase 1 (DNMT1) mRNA expression and (2) reducing the binding of DNMT1 and the methyl-CpG binding protein 2 (MeCP2) to the reln promoter. The present study showed that prenatal dexamethasone exposure induced gross alterations in hippocampal morphology and reduced the levels of hippocampal mRNA expression of reln and GAD1. Spatial memory was unimpaired. Thus, melatonin had a beneficial effect in restoring hippocampal reln mRNA expression by reducing DNMT1 and MeCP2 binding to the reln p romoter.

1.
Matthews SG, Owen D, Banjanin S, Andrews MH: Glucocorticoids, hypothalamo-pituitary-adrenal (HPA) development, and life after birth. Endocr Res 2002;28:709-718.
2.
Huang LT: The link between perinatal glucocorticoids exposure and psychiatric disorders. Pediatr Res 2011;69:19R-25R.
3.
Tain YL, Chen CC, Sheen JM, Yu HR, Tiao MM, Kuo HC, Huang LT: Melatonin attenuates prenatal dexamethasone-induced blood pressure increase in a rat model. J Am Soc Hypertens 2014;8:216-226.
4.
Tiao MM, Huang LT, Chen CJ, Sheen JM, Tain YL, Chen CC, Kuo HC, Huang YH, Tang KS, Chu EW, Yu HR: Melatonin in the regulation of liver steatosis following prenatal glucocorticoid exposure. Biomed Research Int 2014;2014:942172.
5.
Woods SM, Melville JL, Guo Y, Fan MY, Gavin A: Psychosocial stress during pregnancy. Am J Obstet Gynecol 2010;202:61.e1-e7.
6.
Schlotz W, Phillips DI: Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun 2009;23:905-916.
7.
Matrisciano F, Tueting P, Maccari S, Nicoletti F, Guidotti A: Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology 2012;37:929-938.
8.
Matrisciano F, Tueting P, Dalal I, Kadriu B, Grayson DR, Davis JM, Nicoletti F, Guidotti A: Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013;68:184-194.
9.
Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E: Gabaergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology 2005;180:191-205.
10.
Grayson DR, Guidotti A: The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013;38:138-166.
11.
Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C: Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 2001;8:723-742.
12.
Levenson JM, Qiu S, Weeber EJ: The role of reelin in adult synaptic function and the genetic and epigenetic regulation of the reelin gene. Biochim Biophys Acta 2008;1779:422-431.
13.
Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S: Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 2007;27:11254-11262.
14.
Mueller BR, Bale TL: Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci 2008;28:9055-9065.
15.
Kofink D, Boks MP, Timmers HT, Kas MJ: Epigenetic dynamics in psychiatric disorders: environmental programming of neurodevelopmental processes. Neurosci Biobehav Rev 2013;37:831-845.
16.
Huang LT: Early-life stress impacts the developing hippocampus and primes seizure occurrence: cellular, molecular, and epigenetic mechanism. Front Mol Neurosci 2014;7:1-15.
17.
Baserga M, Hale MA, Wang ZM, Yu X, Callaway CW, McKnight RA, Lane RH: Uteroplacental insufficiency alters nephrogenesis and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertension. Am J Physiol Regul Integr Comp Physiol 2007;292:R1943-R1955.
18.
Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V, Carletto A, Pattini P, Corrocher R, Olivieri O: Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 2008;199:323-327.
19.
Baserga M, Kaur R, Hale MA, Bares A, Yu X, Callaway CW, McKnight RA, Lane RH: Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11beta-hydroxysteroid dehydrogenase type 2 in a sex-specific manner. Am J Physiol Regul Integr Comp Physiol 2010;299:R334-R342.
20.
Roth TL, Lubin FD, Funk AJ, Sweatt JD: Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry 2009;65:760-769.
21.
Baxi DB, Singh PK, Vachhrajani KD, Ramachandran AV: Plasticity changes in adult metabolic homeostasis and tissue oxidative stress: neonatal programming by corticosterone and melatonin as deprogrammer. J Matern Fetal Neonatal Med 2012;25:831-844.
22.
Korkmaz A: Epigenetic actions of melatonin. J Pineal Res 2009;46:117-118.
23.
Chen YC, Tain YL, Sheen JM, Huang LT: Melatonin utility in neonates and children. J Formos Med Assoc 2012;111:57-66.
24.
Morley-Fletcher S, Mairesse J, Soumier A, Banasr M, Fagioli F, Gabriel C, Mocaer E, Daszuta A, McEwen B, Nicoletti F, Maccari S: Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 2011;217:301-313.
25.
Tain YL, Huang LT, Lin IC, Lau YT, Lin CY: Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res 2010;49:390-398.
26.
Avishai-Eliner S, Brunson KL, Sandman CA, Baram TZ: Stressed-out, or in (utero)? Trends Neurosci 2002;25:518-524.
27.
Holder MK, Blaustein JD: Puberty and adolescence as a time of vulnerability to stressors that alter neurobehavioral processes. Front Neuroendocrinol 2014;35:89-110.
28.
Yang SN, Huang CB, Yang CH, Lai MC, Chen WF, Wang CL, Wu CL, Huang LT: Impaired SynGAP expression and long-term spatial learning and memory in hippocampal CA1 area from rats previously exposed to perinatal hypoxia-induced insults: beneficial effects of A68930. Neurosci Lett 2004;371:73-78.
29.
Huang LT, Chen CC, Sheen JM, Chen YJ, Hsieh CS, Tain YL: The interaction between high ammonia diet and bile duct ligation in developing rats: assessment by spatial memory and asymmetric dimethylarginine. Int J Dev Neurosci 2010;28:169-174.
30.
Lui CC, Wang JY, Tain YL, Chen YC, Chang KA, Lai MC, Huang LT: Prenatal stress in rat causes long-term spatial memory deficit and hippocampus MRI abnormality: differential effects of postweaning enriched environment. Neurochem Int 2011;58:434-441.
31.
Kreider ML, Tate CA, Cousins MM, Oliver CA, Seidler FJ, Slotkin TA: Lasting effects of developmental dexamethasone treatment on neural cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, dose-effect relationships, regional targets, and sex selectivity. Neuropsychopharmacology 2006;31:12-35.
32.
Bingham BC, Sheela Rani CS, Frazer A, Strong R, Morilak DA: Exogenous prenatal corticosterone exposure mimics the effects of prenatal stress on adult brain stress response systems and fear extinction behavior. Psychoneuroendocrinology 2013;38:2746-2757.
33.
Brabham T, Phelka A, Zimmer C, Nash A, Lopez JF, Vazquez DM: Effects of prenatal dexamethasone on spatial learning and response to stress is influenced by maternal factors. Am J Physiol Regul Integr Comp Physiol 2000;279:R1899-R1909.
34.
Kreider ML, Levin ED, Seidler FJ, Slotkin TA: Gestational dexamethasone treatment elicits sex-dependent alterations in locomotor activity, reward-based memory and hippocampal cholinergic function in adolescent and adult rats. Neuropsychopharmacology 2005;30:1617-1623.
35.
Emgard M, Paradisi M, Pirondi S, Fernandez M, Giardino L, Calza L: Prenatal glucocorticoid exposure affects learning and vulnerability of cholinergic neurons. Neurobiol Aging 2007;28:112-121.
36.
Hauser J, Feldon J, Pryce CR: Direct and dam-mediated effects of prenatal dexamethasone on emotionality, cognition and HPA axis in adult Wistar rats. Horm Behav 2009;56:364-375.
37.
Oliveira M, Bessa JM, Mesquita A, Tavares H, Carvalho A, Silva R, Pego JM, Cerqueira JJ, Palha JA, Almeida OF, Sousa N: Induction of a hyperanxious state by antenatal dexamethasone: a case for less detrimental natural corticosteroids. Biol Psychiatry 2006;59:844-852.
38.
Zuena AR, Mairesse J, Casolini P, Cinque C, Alema GS, Morley-Fletcher S, Chiodi V, Spagnoli LG, Gradini R, Catalani A, Nicoletti F, Maccari S: Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One 2008;3:e2170.
39.
Roch C, Leroy C, Nehlig A, Namer IJ: Predictive value of cortical injury for the development of temporal lobe epilepsy in 21-day-old rats: an MRI approach using the lithium-pilocarpine model. Epilepsia 2002;43:1129-1136.
40.
Fabene PF, Sbarbati A: In vivo MRI in different models of experimental epilepsy. Curr Drug Targets 2004;5:629-636.
41.
Eriksson SH, Free SL, Thom M, Martinian L, Symms MR, Salmenpera TM, McEvoy AW, Harkness W, Duncan JS, Sisodiya SM: Correlation of quantitative MRI and neuropathology in epilepsy surgical resection specimens - T2 correlates with neuronal tissue in gray matter. Neuroimage 2007;37:48-55.
42.
Jansen JF, Lemmens EM, Strijkers GJ, Prompers JJ, Schijns OE, Kooi ME, Beuls EA, Nicolay K, Backes WH, Hoogland G: Short- and long-term limbic abnormalities after experimental febrile seizures. Neurobiol Dis 2008;32:293-301.
43.
Mychasiuk R, Gibb R, Kolb B: Prenatal bystander stress induces neuroanatomical changes in the prefrontal cortex and hippocampus of developing rat offspring. Brain Res 2011;1412:55-62.
44.
Sierksma AS, Prickaerts J, Chouliaras L, Rostamian S, Delbroek L, Rutten BP, Steinbusch HW, van den Hove DL: Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice. Neurobiol Aging 2013;34:319-337.
45.
Guidotti A, Auta J, Chen Y, Davis JM, Dong E, Gavin DP, Grayson DR, Matrisciano F, Pinna G, Satta R, Sharma RP, Tremolizzo L, Tueting P: Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011;60:1007-1016.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.